This strategy is supported by in vitro evidence showing improved T-cell function following IL2RA upregulation, suggesting that future clinical trials should explore this approach to enhance TCR-T therapies in hostile tumor microenvironments (34). This evidence concerns the gene IL2RA and neoplasm.